MCL-1 may provide an alternative protection against apoptosis in SS; Fairchild et al. [63] showed that targeting MCL-1 (either through expression of the MCL-1 inhibitor NOXA or treatment with the BH3 mimetic S63845) sensitizes SS cells to venetoclax [63]. This evidence concerns the gene MCL1 and synovial sarcoma.